Table 1.
Association of antibody response to FliC with adenoma/CRC in the Nijmegen/Detroit and MCC-Spain studies.
| Study | FliC | Total n (%) | Controls n (%) | Casesa n (%) | OR (95%CI)b | ptrend |
|---|---|---|---|---|---|---|
| Nijmegen/Detroit studies | Q1 | 38 (23) | 19 (26) | 19 (20) | ref | |
| Q2 | 29 (17) | 19 (26) | 10 (11) | 0.53 (0.20–1.43) | ||
| Q3 | 37 (22) | 17 (23) | 20 (22) | 1.18 (0.48–2.91) | ||
| Q4 | 63 (38) | 19 (26) | 44 (47) | 2.32 (1.01–5.33) | 0.011 | |
| MCC-Spain | Q1 | 296 (26) | 145 (25) | 151 (26) | ref | |
| Q2 | 254 (22) | 143 (25) | 111 (19) | 0.75 (0.53–1.06) | ||
| Q3 | 288 (25) | 144 (25) | 144 (25) | 0.99 (0.70–1.38) | ||
| Q4 | 314 (27) | 144 (25) | 170 (30) | 1.14 (0.81–1.59) | 0.247 |
aCases include n = 23 adenoma and n = 70 CRC cases for Nijmegen/Detroit studies, all cases were CRC in MCC Spain; bLogistic regression model, Nijmegen/Detroit study: no further adjustment, MCC-Spain: adjustment for age, sex, province, education, BMI, smoking and family history of CRC; significant associations (p-value < 0.05) are marked in bold font; Q = quartile.